Atezolizumab is the first humanized anti-PD-L1 monoclonal immunoglobulin G1 antibody approved by the U.S. Food and Drug Administration (FDA), which binds to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocked its interaction with the interaction of PD-1 and B7.1 receptor, restores T cell function, and relieves inhibition of the body’s immune system against tumor cells (56, 57). Here, PDCD1 is linked to neoplasm.